HC Wainwright & Co. Reiterates Buy on CymaBay Therapeutics, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and maintains a $12 price target.
June 26, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on CymaBay Therapeutics and maintains a $12 price target.
The reiterated Buy rating and maintained $12 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for CymaBay Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100